MedChemExpress LLC reported that Rusfertide was approved as a hepcidin mimetic for polycythemia vera in August 2026.

Public source

Publisher name

Public post

💊#FDA Drug Approvals — August 2026 🔬First-in-class breakthroughs • #Daraxonrasib — a #RAS inhibitor for metastatic pancreatic cancer • #Rusfertide — a hepcidin mimetic…

Log in to read the full post

Company

MedChemExpress LLC

Master of Bioactive Molecules.

Industry
Biotechnology Research
Location
Monmouth Junction, US
Company size
51–200 employees

About MedChemExpress LLC

MedChemExpress (MCE) is a leading global supplier of life science reagents, dedicated to providing innovative solutions for scientific research and drug development. We offer a comprehensive range of high-quality active molecules, including inhibitors, compound libraries, recombinant proteins, antibodies, and more, positioning itself as a leading global supplier of research chemicals and bioactive compounds. Headquartered in New Jersey, USA, MCE has established multiple R&D, production, and logistics centers worldwide. With a team of seasoned experts, MCE has built an end-to-end service system, encompassing services such as HNMR data analysis, bioactivity evaluation, technical consultation, and after-sales support. Backed by stringent management systems and quality control standards, MCE delivers efficient, precise, and reliable services to over 15,000 research institutions worldwide. Committed to driving innovation in drug discovery, MCE is your trusted long-term partner for scientific exploration and pharmaceutical research.   https://linktr.ee/MedChemExpress

See more

Latest activity

14 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.